Latest news with #ColgatePalmolive
Yahoo
11 hours ago
- Business
- Yahoo
Jim Cramer Notes 'Colgate Quarter Was Darn Good'
Colgate-Palmolive Company (NYSE:CL) is one of the stocks on Jim Cramer's radar. A caller highlighted that the stock seems to be going down despite reaffirming its guidance. Cramer remarked: 'The best one in the group, by the way, is Kimberly. Mike Hsu did an amazing job. Kimberly is the right one. Now I will say this, I thought the Colgate quarter was darn good. I like the Hill's. I think Total's doing amazingly well. I don't understand why it's acting the worst of all of them. Maybe it's because of the high multiple, but I would not abort. I would not leave Colgate right here. I just can't. But boy, that's, that's it. Noel Wallace, come on the show. I know you don't like media, but you know this is the right place to go.' Stock market data. Photo by Photo by Alesia Kozik Colgate-Palmolive (NYSE:CL) produces oral care, personal care, home cleaning, and skin health products under brands like Colgate, Palmolive, Irish Spring, and Softsoap. In addition, the company provides pet nutrition products through Hill's Science Diet and Hill's Prescription Diet. While we acknowledge the potential of CL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Colgate-Palmolive Stock: Is Wall Street Bullish or Bearish?
Valued at a market cap of $67.7 billion, Colgate-Palmolive Company (CL) is a global consumer goods giant specializing in oral care, personal care, home care, and pet nutrition, with popular brands like Colgate, Palmolive, Softsoap, and Hill's Pet Nutrition. Headquartered in New York, the company operates in over 200 countries through Oral, Personal & Home Care and Pet Nutrition segments. The oral hygiene giant has lagged behind the broader market, declining 18.9% over the past year and 8.3% on a YTD basis. In contrast, the S&P 500 Index ($SPX) has surged 18.4% over the past year and 7.6% in 2025. More News from Barchart Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Narrowing the focus, CL has also underperformed the Consumer Staples Select Sector SPDR Fund's (XLP) 1.6% gains over the past year and 2.5% rally in 2025. CL shares slid marginally on Aug. 1 after the company posted its fiscal 2025 second-quarter earnings. It reported net sales of $5.11 billion, up 1% year-over-year, with organic sales growing 1.8%. Adjusted EPS of $0.92 slightly beat analyst expectations. Colgate maintained its global leadership in oral care in 2025, holding a 41.1% share of the toothpaste market and a 32.4% share of the manual toothbrush market. For the current fiscal year 2025, ending in December, analysts expect CL to report a 1.9% year-over-year increase in adjusted EPS to $3.67. The company has a solid earnings surprise history. It has surpassed the Street's bottom-line estimates in each of the past four quarters. The stock holds a consensus 'Moderate Buy' rating overall. Of the 20 analysts covering the CL stock, opinions include 10 'Strong Buys,' two 'Moderate Buys,' six 'Holds,' and two 'Strong Sells.' This configuration is more bearish than three months ago, when the stock had 11 'Strong Buy' ratings. On August 4, Citigroup Inc. (C) analyst Filippo Falorni reaffirmed a "Buy" rating on Colgate-Palmolive but lowered the price target from $108 to $105, reflecting a 2.8% reduction. CL's mean price target of $98 represents a premium of 17.6% to current price levels, while its Street-high target of $108 suggests a 29.6% potential upside. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Techday NZ
4 days ago
- Business
- Techday NZ
Armis surpasses USD $300 million in annual recurring revenue
Armis has reported that it has exceeded USD $300 million in annual recurring revenue after registering an increase from USD $200 million in under twelve months. The company provides cyber exposure management and security for a wide range of global organisations, which include United Airlines, Colgate Palmolive, and Mondelez, as well as more than a third of the Fortune 100 and numerous federal agencies and states. According to Armis, its client base also accounts for 60% of Fortune 10 companies, three of the five largest US retailers, three of the five largest banks, and several other major enterprises. The company's technology protects operational technology (OT), Internet of Things (IoT), information technology (IT), and medical environments, assisting organisations in addressing vulnerabilities from software code to cloud infrastructure. Revenue milestone Armis attributes this rapid increase in annual recurring revenue to a significant demand among global organisations for the Armis Centrix platform and related products. The company states that organisations are increasingly adopting Armis' offerings to gain improved visibility, protection, and management of their entire digital attack surface. "Surpassing another $100m milestone in ARR so quickly proves we have the right platform, the right set of products and our customers are using Armis for complete cyber risk exposure management and security," said Yevgeny Dibrov, CEO and Co-Founder of Armis. "Customers globally are excited about our roadmap and recognise the vital role we play being one of their most important security providers. I want to thank all our customers, partners and the Armis team for their continued delivery as we secure the most critical environments of every major organisation and vertical." Partner focus The company has increased its efforts to expand partner engagement and boost revenue generated by strategic partnerships. With contracts signed with several large Global Systems Integrators, Armis has sought to make its cyber exposure management solution more accessible to organisations around the world. Its partner ecosystem now includes organisations such as AWS, KPMG, Accenture, PWC, Fortinet, Guidepoint, WWT, Google, and numerous others. Armis has also grown its physical presence, recently opening offices in Munich, London, Bucharest and New York. Over the past year, the company expanded its product portfolio by releasing three new products and made several technology acquisitions. These developments have extended its expertise in OT and cyber-physical systems (CPS) security, now enabling support for environments that are airgapped or disconnected from the internet through new hybrid and on-premises offerings. Product development and growth "The investments we've made in organic and inorganic product development and in building the strong go-to-market machine we have built are paying off and driving huge momentum," said Jonathan Carr, Chief Financial Officer of Armis. "Each technology that we develop works together, creating a better together story for our customers and enabling us to address security in ways that just were not possible before. We strive to help organisations move from 'detect and then respond' to a more proactive approach that allows them to protect their organisations before an attack happens. The results we have seen have been a great validation of this approach and we are poised to have our best year yet, growing in excess of top public company benchmarks." Armis reports that its growth and product development are driven by both internal development efforts and acquisitions. The company states that the combined capabilities of its different technologies create a unified offering for its customers. Analyst recognition Industry analysts such as Gartner, Forrester and IDC have ranked Armis in their reports. Most recently, Armis was named a Leader in the Gartner Magic Quadrant for CPS Protection Platforms and as a Leader in The Forrester Wave: Unified Vulnerability Solutions, Q3 2025. Armis' Centrix platform and suite of solutions continue to be demonstrated in partnership with organisations across various cities as part of the Armis Connect roadshow series, highlighting cybersecurity challenges and their approaches to addressing them.
Yahoo
01-08-2025
- Business
- Yahoo
Colgate-Palmolive, Rocket, Regeneron: Trending Tickers
Colgate-Palmolive (CL) stock is in focus after the company warned of a "persistently cautious consumer" in North America, even as it reported strong second quarter results and announced cost-cutting initiatives to boost long-term growth. Rocket Companies (RKT) stock is rising on strong second quarter earnings and upbeat third quarter guidance, seeing demand expected to accelerate through the extended home-buying season. Regeneron (REGN) reported second quarter adjusted earnings per share that came in above estimates, driven by strong sales of its drug Eylea HD. To watch more expert insights and analysis on the latest market action, check out more Market Domination. Now time for some of today's trending tickers, where watching shares of Colgate Palmolive, Rocket companies and Regeneron. Let's start with Colgate Palmolive, the company warning of a quote, persistently cautious consumer in North America. CEO Noel Wallace say sees that uncertainty holding in the short term, but potentially getting better as we exit 2025. The warning comes despite the company's beat, by the way, on the top and bottom lines of the second quarter. Organic sales in Q2 did beat estimates, while the company sees sales at the low end of a 2% to 4% gain for the full year. Company also announcing cost cutting initiatives to support long-term efficiency and growth. Meanwhile, Rocket companies popping today on its third quarter guidance and strong earnings for the second quarter. The mortgage provider seeing demand accelerate despite the Federal Reserve holding rates steady. Mortgage volume rose 13% from last year and closed origination volume rose 18%. CEO Brian Brown says that the company remains cautiously optimistic about the summer home buying season, which is expected to extend past Labor Day into the fall. And finally Regeneron, pairing earlier gains after reporting a big beat on adjusted earnings per share of $12.89 in the second quarter. That is 50% more than what analysts had been looking for. The pharmaceuticals manufacturer seeing strong sales of its eye drug, Eylea HD. On Wall Street, Cantor Fitzgerald says Regeneron can meet or beat full year estimates if that eye drug keeps growing, while RBC says strong sales may help the stock rebound. Related Videos Berkshire Hathaway earnings: 'Perfect' stock to own when 'worried' Big Tech's huge AI spending spree: A closer look post-earnings Fed Governor Adriana Kugler to resign Dow falls more than 500 points on jobs report, tariffs Sign in to access your portfolio
Yahoo
01-08-2025
- Business
- Yahoo
Kleenex Maker Stuns Wall Street with Unseen Volume Surge--Is a Consumer Staples Comeback Brewing?
Kimberly-Clark (NASDAQ:KMB) is turning heads again. The consumer goods giant just posted its strongest volume growth in five years, with second-quarter volumes up 5%a rare beat driven entirely by people buying more, not paying more. The company's pivot toward lower-priced products and a refreshed innovation pipeline seems to be resonating with budget-stretched U.S. consumers. Management responded by raising full-year guidance, now expecting low-to-mid-single-digit EPS growth (at constant currency), up from a previous flat-to-slightly-positive outlook. That includes a one-time 16-cent boost tied to its $3.4 billion international tissue divestment, which also helped sharpen focus on core North American categories. It's not just Kimberly-Clark seeing signs of life. Colgate-Palmolive (NYSE:CL) reported better-than-expected organic sales growth as its North American business showed improvement. Meanwhile, Procter & Gamble (NYSE:PG) projected up to 4% revenue growth for the current fiscal yearfaster than last year and ahead of consensus. Together, these signals suggest that after a bruising start to the year, consumers could be regaining confidence and spending more on everyday essentials. Just last quarter, the group saw its first organic sales contraction in more than three years, as macro pressures and geopolitical volatility weighed on household budgets. Still, not everyone is catching the same tailwind. Church & Dwight's (NYSE:CHD) organic sales shrank in its domestic segment, and its stock barely budged. In contrast, Kimberly-Clark shares surged as much as 7.9% on the news, though they remain down 4.9% year-to-dateunderperforming the broader market. CEO Mike Hsu struck a measured tone, warning that consumer purchasing power remains under pressure, with no near-term catalyst for change. But if the March 2024 turnaround plan is finally gaining traction, Kimberly-Clark's positioning across value tiers could help it ride the next wave of consumer staples recovery. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
